We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2011 by Bispebjerg Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01349361
First Posted: May 6, 2011
Last Update Posted: May 6, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Bispebjerg Hospital
  Purpose
Photodynamic Therapy (PDT) is an effective treatment of basal cell carcinomas (BCC) however the inconvenience of clinic attendance and discomfort during therapy are significant drawbacks. The objective of this study is to evaluate the effect of daylight-mediated PDT of BCC.

Condition Intervention Phase
Photodynamic Therapy Basal Cell Carcinomas Procedure: Daylight mediated photodynamic therapy Phase 2

Study Type: Interventional
Official Title: Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight

Resource links provided by NLM:


Further study details as provided by Bispebjerg Hospital:

Primary Outcome Measures:
  • complete disappearance of the BCC

Study Start Date: March 2011
Estimated Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Daylight-PDT Procedure: Daylight mediated photodynamic therapy

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • superficial BCC

Exclusion Criteria:

  • Immunosuppression
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01349361


Contacts
Contact: Stine R Wiegell, MD, PhD swie0001@bbh.regionh.dk

Locations
Denmark
Bispebjerg Hospital Recruiting
Copenhagen NV, Denmark, 2400
Contact: Stine R Wiegell, MD, PhD       swie0001@bbh.regionh.dk   
Principal Investigator: Stine R Wiegell, MD, PhD         
Sponsors and Collaborators
Bispebjerg Hospital
  More Information

Responsible Party: Hans Christian Wulf, Bispebjerg Hospital
ClinicalTrials.gov Identifier: NCT01349361     History of Changes
Other Study ID Numbers: 2010-024517-31
First Submitted: May 5, 2011
First Posted: May 6, 2011
Last Update Posted: May 6, 2011
Last Verified: March 2011

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Basal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Basal Cell
Aminolevulinic Acid
Methyl 5-aminolevulinate
Photosensitizing Agents
Dermatologic Agents